|
Subject ID
|
Treatment
|
|---|
|
5-FU + FA
|
FOLFIRI
|
FOLFOX
|
|---|
|
01
|
S
|
S
|
S
|
|
02a
|
S
|
S
|
I
|
|
03
|
S
|
S
|
S
|
|
04a
|
R
|
I
|
I
|
|
05a
|
I
|
R
|
R
|
|
06
|
I
|
N/D
|
N/D
|
|
07a
|
S
|
I
|
I
|
|
08a
|
I
|
I
|
I
|
|
09
|
R
|
S
|
S
|
|
10a
|
I
|
R
|
S
|
|
11
|
I
|
R
|
I
|
|
12a
|
I
|
I
|
I
|
|
13a
|
S
|
I
|
I
|
|
14
|
I
|
I
|
S
|
|
15a
|
I
|
R
|
R
|
|
16a
|
I
|
R
|
R
|
|
17a
|
I
|
I
|
R
|
|
18a
|
R
|
S
|
I
|
|
19a
|
R
|
I
|
I
|
- Results were categorized according to percentile thresholds (R = resistant < 25th percentile < I = intermediate sensitive < 75th percentile < S = sensitive; N/D = not determined). Oncogramme results for treatments that were actually given to patients are underlined
-
aIndicates the 13 patients selected for the supplementary analysis, which were those who received equivalent chemotherapeutic treatments over the course of at least two evaluations
